Navigation Links
Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Date:11/26/2007

BERKELEY HEIGHTS, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview and update of corporate activities at the Lazard Capital Markets 4th Annual Healthcare Conference. Genta's presentation is scheduled for Wednesday, November 28th at 8:00 am EST at the New York Palace Hotel, New York, NY.

The presentation will be webcast and accessible at the Investor Relations section of the Company's website at: http://www.genta.com/investorrelation/events.html. The presentation will be archived for 30 days.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which is currently undergoing initial clinical trials as a potential treatment for diseases associated with accelerated bo
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
8. Accuray Incorporateds CEO to Speak at Piper Jaffray 19th Annual Health Care Conference
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Avicena Group to Present at Noble Financial Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... , TOKYO, Japan, August 3 ... June 30, 2009. Net,sales were 94.9 billion yen for the ... period last year, and operating income was 9.2,billion yen, a ... last,year, mainly due to order decrease and the impact of ...
... ... Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) in India from October 6-10, ... Development of Sustainable Non-Food Jatropha and other Oil Crop Projects, Programmes and ... lot of milestones since last year,s event, and a number of alternative ...
... , , , , ... Calif., Aug. 2 Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, ... exclusive license and collaboration agreement to commercialize Intermezzo ((R)) (zolpidem ... U.S. Food and Drug Administration (FDA), Intermezzo ((R)) has the ...
Cached Biology Technology:Hoya Announces First Quarter Financial Results for FY2010 2Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 2Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 3Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 4Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 2Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 3Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 4Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 5Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 6Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 7
(Date:12/15/2014)... Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced the ... report to their offering. ... technology used for the identification of individuals. Facial recognition ... such as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... percent of energy in the U.S. is produced by coal. ... A professor in the College of Engineering at the ... Department of Energy to help change that. ... Materials Science and Engineering, and colleagues have received a $300,000 ...
... ,PROVIDENCE, R.I. [Brown University] Selenium is an inexpensive ... also known to combat bacteria. Still, it had not ... device material. In a new study, Brown University engineers ... polycarbonate, the material of catheters and endotracheal tubes, the ...
... messages, from bananas to home-grown tomatoes: everything we buy, produce or ... a "footprint". And if you want to be a good global ... use to understand just how big your footprint is or ... But what if you are a government decision maker and want ...
Cached Biology News:University of Tennessee professor receives funding for clean coal research 2Selenium suppresses staph on implant material 2Selenium suppresses staph on implant material 3A virtual crystal ball 2A virtual crystal ball 3A virtual crystal ball 4
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Biology Products: